Genetic Testing: New Medicare Early NGS Cancer Test Coverage Policy Is Less than Meets the Eye

摘要

For Myriad Genetics, Foundation Medicine and other manufactureps of next-generation sequencing (NGS)-based test panels for early tage cancer risk assessment, the recent announcement of CMS fecision to provide limited Medicare coverage for gemline breast and ovarian cancer looks like positive new But while a lot better than the previous version, the propose National Coverage Determination (NCD) is much less than even the half a loaf it looks like.